bulaquine and Malaria--Vivax

bulaquine has been researched along with Malaria--Vivax* in 2 studies

Trials

2 trial(s) available for bulaquine and Malaria--Vivax

ArticleYear
Safety and tolerability of elubaquine (bulaquine, CDRI 80/53) for treatment of Plasmidium vivax malaria in Thailand.
    The Korean journal of parasitology, 2006, Volume: 44, Issue:3

    We conducted a study to compare the safety and tolerability of anti-relapse drugs elubaquine and primaquine against Plasmodium vivax malaria. After standard therapy with chloroquine, 30 mg/kg given over 3 days, 141 patients with P. vivax infection were randomized to receive primaquine or elubaquine. The 2 treatment regimens were primaquine 30 mg once daily for 7 days (group A, n = 71), and elubaquine 25 mg once daily for 7 days (group B, n = 70). All patients cleared parasitemia within 7 days after chloroquine treatment. Among patients treated with primaquine, one patient relapsed on day 26; no relapse occurred with elubaquine treatement. Both drugs were well tolerated. Adverse effects occurred only in patients with G6PD deficiency who were treated with primaquine (group A, n = 4), whose mean hematocrit fell significantly on days 7, 8 and 9 (P = 0.015, 0.027, and 0.048, respectively). No significant change in hematocrit was observed in patients with G6PD deficiency who were treated with elubaquine (group B, n = 3) or in patients with normal G6PD. In conclusion, elubaquine, as anti-relapse therapy for P. vivax malaria, was as safe and well tolerated as primaquine and did not cause clinically significant hemolysis.

    Topics: Adolescent; Adult; Animals; Antimalarials; Chloroquine; Female; Humans; Malaria, Vivax; Male; Middle Aged; Plasmodium vivax; Primaquine; Prospective Studies; Thailand

2006
Plasmodium vivax polymorphism in a clinical drug trial.
    Clinical and diagnostic laboratory immunology, 2001, Volume: 8, Issue:5

    Data from a double-blind randomized clinical drug trial were analyzed to find the comparative responses of two antirelapse drugs, bulaquine and primaquine, against different relapsing forms of Plasmodium vivax infection. A 1-year follow-up study strongly suggests that the duration of preerythrocytic development of P. vivax is a polymorphic characteristic, exhibited by two strains of hypnozoites responsible for early and late manifestations after primary infection. Short-term relapses were significantly higher in the first half year than long-term relapses, and the reverse was true in the second half year. Clinical drug response data showed that the hypnozoites characterized for short-term relapse were not susceptible to either of the antirelapse drugs in the currently administered dose, whereas hypnozoites characterized for long incubation were significantly susceptible.

    Topics: Administration, Oral; Animals; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Follow-Up Studies; Genetic Variation; Humans; Malaria, Vivax; Phenotype; Plasmodium vivax; Polymorphism, Genetic; Primaquine; Secondary Prevention

2001